Author: Cecylia S. Lupala; Xuanxuan Li; Jian Lei; Hong Chen; Jianxun Qi; Haiguang Liu; Xiao-dong Su
                    Title: Computational simulations reveal the binding dynamics between human ACE2 and the receptor binding domain of SARS-CoV-2 spike protein  Document date: 2020_3_27
                    ID: kifqgskc_1
                    
                    Snippet: The outbreak of a new type of severe pneumonia COVID-19 started in December 2019 1 has been going on world-wide, and caused over 15,000 fatalities, infected more than 96% compared to the closest bat coronavirus RaTG13, about 89% compared to two other bat SARS-like viruses (Bat-SL-CoVZC45 & Bat-SL-CoVZXC21), and 79% compared to the SARS-CoV 3, 4 . Furthermore, the SARS-CoV-2 spike protein has a protein sequence identity of 73% for the receptor bin.....
                    
                    
                    
                     
                    
                    
                    
                    
                        
                            
                                Document: The outbreak of a new type of severe pneumonia COVID-19 started in December 2019 1 has been going on world-wide, and caused over 15,000 fatalities, infected more than 96% compared to the closest bat coronavirus RaTG13, about 89% compared to two other bat SARS-like viruses (Bat-SL-CoVZC45 & Bat-SL-CoVZXC21), and 79% compared to the SARS-CoV 3, 4 . Furthermore, the SARS-CoV-2 spike protein has a protein sequence identity of 73% for the receptor binding domain (RBD) with the SARS-CoV RBD (denoted as SARS-RBD in the following). The SARS-CoV and SARS-CoV-2 both utilize the human Angiotensin converting enzyme 2 protein (ACE2) to initiate the spike protein binding and facilitate the fusion to host cells [5] [6] [7] [8] [9] . The 193-residue RBD of the SARS-CoV spike protein has been found to be sufficient to bind the human ACE2 6 . Based on this fact, the RBD of SARS-CoV-2 becomes a critical protein target for drug development to treat the COVID-19. When this study was started, neither the crystal structure of the SARS-CoV-2 spike protein nor the RBD segment were determined, so the homology modeling approach was applied to construct the model of the SARS-CoV-2 spike RBD in complex with the human ACE2 binding domain (denoted as CoV2-RBD/ACE2 in the following).
 
  Search related documents: 
                                Co phrase  search for related documents- bind domain and crystal structure: 1, 2, 3, 4, 5, 6, 7
  - bind domain and drug development: 1
  - bind domain and human Angiotensin utilize: 1
  - bind domain and protein bind: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57
  - bind domain and protein sequence: 1, 2, 3
  - bind domain and protein sequence identity: 1
  - bind domain and protein target: 1, 2, 3, 4
  - bind domain and RBD receptor bind domain: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51
  - bind domain and receptor bind domain: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
  - bind domain and SARS CoV spike protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
  - bind domain and SARS spike: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49
  - bind domain and SARS spike protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
  - bind domain and severe pneumonia: 1
  - bind domain and spike protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60
  - bind domain and spike protein bind: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27
  - cell host and crystal structure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41
  - cell host and drug development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
  - cell host and drug development protein target: 1, 2, 3
  - cell host and fatality cause: 1, 2, 3
  
 
                                Co phrase  search for related documents, hyperlinks ordered by date